Contract research and manufacturing services (CRAMS) refer to the practise of contracting out product development and research services to businesses that can do so at a reasonable price. It is a procedure whereby the product's parent firm does not actually produce the item themselves. The main types of services provide by contract research and manufacturing services (CRAMS) are manufacturing and research. Manufacturing services include outsourcing drug development services to companies operating in the pharmaceutical or biotechnology industry on a contract basis. The contract manufacturing organizations are involved in the entire development process, right from the clinical trial and phases till the commercialization of the drugs. Research services outsourcing of research services such as clinical trial data management, database design and build, data entry and validation, medicine and disease coding, project management, quality, and metric reporting, safety and efficacy summaries, statistical analysis plans and reports, on a contract basis. The contract research and manufacturing services (CRAMS) are used by pharmaceutical & biotechnology companies, medical device companies, and academic institutes. The contract research and manufacturing services (CRAMS) market research report is one of a series of new reports from The Business Research Company that provides contract research and manufacturing services (CRAMS) market statistics, including contract research and manufacturing services (CRAMS) industry global market size, regional shares, competitors with a contract research and manufacturing services (CRAMS) market share, detailed contract research and manufacturing services (CRAMS) market segments, market trends and opportunities, and any further data you may need to thrive in the contract research and manufacturing services (CRAMS) industry. This contract research and manufacturing services (CRAMS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global contract research and manufacturing services (CRAMS) market size grew from $120.23 billion in 2022 to $129.97 billion in 2023 at a compound annual growth rate (CAGR) of 8.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The contract research and manufacturing services (CRAMS) market size is expected to grow to $183.81 billion in 2027 at a CAGR of 9.1%. The rising ageing population with various chronic diseases is expected to have a positive impact on the growth of the contract research and manufacturing services market in the forecast period. The world's ageing population is growing rapidly and is expected to continue over the forecast period. With the increase in the geriatric population, the prevalence of various diseases like cancer, diabetes, Alzheimer’s, arthritis, and other diseases will also rise, and the demand for various drugs or medicines will increase. As a result, the need for contract research and manufacturing services will grow. For instance, as of 2020, there were 727 million people above the age of 65, which constituted 9.3% of the world population, and it is expected to increase to around 16.0 % in 2050. According to the National Center for Biotechnology Information, about 60% of cancer cases occur in people 65 years of age and older, and 70% of deaths are caused by cancer at this stage. Therefore, the increasing age of the population with various chronic diseases will drive the contract research and manufacturing services market growth. Artificial intelligence (AI) is increasingly being used by the contract research and manufacturing services (CRAMS) market to strengthen its market position. Artificial intelligence is a branch of computer science dealing with the simulation of human behavior in machines. AI can help to avoid costly maintenance by predicting when maintenance is needed by supporting the healthcare system. For instance, in May 2021, the Center for Artificial Intelligence, a part of the Saudi Data and Artificial Intelligence Authority (SDAIA), signed a memorandum of understanding (MOU) with IQVIA for exploring opportunities of mutual interest to advance innovation in the field of healthcare data in the Kingdom by developing common ideas and research in the field of data and artificial intelligence. In addition, IQVIA launched the Avacare clinical research network in February 2020, a technology-based global site network that provides an opportunity for more clinical trials at experienced clinical and research sites. Avacare uses innovative clinical technology with advanced analytics to deliver artificial intelligence-based patient recommendations and data-driven registration. In April 2021, Thermo Fisher Scientific, a US-based company offering scientific instrumentation, reagents, consumables, and software services announced the acquisition of the clinical research services provider PPD for a total of $17.4 billion. Through this acquisition, PPD will become part of Thermo Fisher's laboratory products and services business and will provide pharmaceutical and biotechnology customers with a series of clinical research and laboratory services to help them improve the efficacy of drug development. Pharmaceutical Product Development (PPD), was founded in 1985 and is headquartered in the United States. It is a global contract research organization (CRO) that provides comprehensive and integrated services in the fields of drug development, laboratory, and lifecycle management. Major players in the contract research and manufacturing services (CRAMS) market are Boehringer Ingelheim International GmbH, Catalent Inc., Lonza Group Ltd., Pharmaceutical Product Development LLC, Baxter BioPharma Solutions, AbbVie, Grifols International S.A., and Dalton Pharma Services. North America was the largest region in the contract research and manufacturing services (CRAMS) market in 2022. Asia-Pacific region is expected to grow at a faster pace in the forecast period. The regions covered in contract research and manufacturing services (CRAMS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the contract research and manufacturing services (CRAMS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The contract research and manufacturing services (CRAM) market includes revenues earned by entities by minimizing cost and focusing on more functional areas. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global contract research and manufacturing services (CRAMS) market is segmented - 1) By Services: Manufacturing, Research 2) By End User: Pharmaceutical & Biotechnology Companies, Medical Device Companies, Academic Institutes 

Pharmaceutical contract development and manufacturing refers to a business that offers services for drug research and manufacture within the pharmaceutical sector. Using CDMOs as a partner, pharmaceutical companies can outsource medication development and production. Full-service drug development and manufacturing outsourcing companies (CDMOs) can handle every stage of the process and work with clients that want to outsource specific steps in their workflow. Everything is based on the requirements of each client. The main types of pharmaceutical contract development and manufacturing organisations (CMO) are active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development and manufacturing, and secondary packaging. The active pharmaceutical ingredient (API) manufacturing includes the manufacturing of the part of any drug that produces the desired effects. The various research phases include preclinical, phase I, phase II, phase III, and phase IV. The different end-use sectors include big pharmaceutical companies, generic pharmaceutical companies, and small & medium-sized pharmaceutical companies. The pharmaceutical contract development and manufacturing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical contract development and manufacturing market statistics, including pharmaceutical contract development and manufacturing industry global market size, regional shares, competitors' pharmaceutical contract development and manufacturing market share, detailed pharmaceutical contract development and manufacturing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical contract development and manufacturing industry. This pharmaceutical contract development and manufacturing market research report deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical contract development and manufacturing market grew from $122.31 billion in 2022 to $130.82 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical contract development and manufacturing market is expected to grow from $196.53 billion in 2027 at a CAGR of 10.7%. The growth of the pharmaceutical contract development and manufacturing market is driven by the increase in the demand for medicines across the globe. The high prevalence of diseases and the need for a longer lifespan increased the demand for medicines pushing the pharmaceutical companies to increase the production of existing drugs and raise the investment in their R&D to promote the development of new drugs. This impels the pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) as a way to lower operational costs, thus, increasing the demand for pharmaceutical contract development and manufacturing market. According to Alkermes PLC., a biopharmaceutical company indicates that pharmaceutical contract manufacturing will emerge as a strategic option for many companies ranging from very large to smaller specialty pharma entities and this mostly will happen because the pharmaceuticals companies are looking for cost-cutting. The pharmaceutical contract development and manufacturing market are restricted by the poor-capacity utilization of manufacturing facilities. The capacity utilization is calculated considering the full potential capacity of the production plant. The poor-capacity utilization of the production plant is caused due to the inefficiency of different sub-processes in the production line which results in low production. The low production output results in low revenue generation for the production unit, affecting the overall pharmaceutical contract development and manufacturing market. For instance, in January 2020, according to an article shared by Economic Times, an India-based English-language business-focused daily newspaper, The 1,500 API manufacturing facilities in India, according to the country's drug regulatory organisation, are only operating at 40% of their potential. Therefore, the usage of capacity of the production plant negatively affects the pharmaceutical contract development and manufacturing market. The companies in the pharmaceutical contract development and manufacturing market are investing in acquiring and forming alliances with other companies in the market. The pharmaceutical contract development and manufacturing companies are following the trend of merger and acquisition to expand their global market reach to meet the client needs, increase their production capabilities while maintaining cost efficiencies, and get access to the latest technology and new services. The high levels of merger and acquisition activities are resulting in the consolidation of the contract service providers. For instance, in July 2022, Pharma Nobis, a US-based provider of contract manufacturing and private label services, acquired Fagron’s U.S. contract manufacturing business for an undisclosed amount. Through this acquisition, Pharma Nobis is expected to offer contract manufacturing and private label services to American retailers and consumer healthcare corporations. 20% of the company will continue to be owned by Fagron. In August 2022, Catalent, Inc., a US-based provider of delivery technologies, development, and drug manufacturing, acquired Metrics Contract Services for $475 million. This acquisition is expected to improve Catalent's ability to work with highly potent chemicals while enhancing its expertise in integrated oral solid formulation research, production, and packaging to assist clients in streamlining and accelerating their processes. Metrics Contract Services is a US-based pharmaceutical contract development and manufacturing organization. Major players in the pharmaceutical contract development and manufacturing market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH, Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited, Dishman Pharmaceuticals, HAUPT Pharma AG, Kemwell Pvt. Ltd., Nipro Corp., NextPharma, Royal DSM N.V., Althea Technologies, Thermo Fisher Scientific Inc., Lonza Group Ltd., AbbVie Inc., Consort Medical PLC., Almac Group, Siegfried Holding AG, Evonik Industries AG, and Vetter Pharma International GMBH. North America was the largest region in the global pharmaceutical contract development and manufacturing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical contract development and manufacturing market during the forecast period. The regions covered in the global pharmaceutical contract development and manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical contract development and manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical contract development and manufacturing market includes revenues earned by entities by providing drug development and manufacturing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global pharmaceutical contract development and manufacturing organisation (CMO) market is segmented - 1) By Type: Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging 2) By Research Phase: Preclinical, Phase I, Phase II, Phase III, Phase IV 3) By End-User: Big Pharmaceutical Companies, Generic Pharmaceutical Companies, Small & Medium-Sized Pharmaceutical Companies

Manufacturing analytics refer to a statistical tool that aids in the rule-based analysis of manufacturing data and information, allowing users to better understand the process and hence enhance business operations and product quality. Manufacturing analytics enables to spot an issue before it occurs, which could have an impact on the product, yield, or cost. Manufacturing analytics is used to improve process efficiency and centralize production monitoring. The main types of components in manufacturing analytics are software and service. The software refers to business intelligence (BI) tools for capturing, aggregating, and analyzing manufacturing data analytics. Manufacturing analytics software reveals insights about processes and functions that can lead to improvements at all levels of an organization. The different deployment modes include cloud, and on-premise and are used in several applications such as predictive maintenance, inventory management, supply chain optimization, and others. It is employed in semiconductor and electronics, energy and power, pharmaceutical, automobile, heavy metal and machine manufacturing, and other industry verticals. The manufacturing analytics market research report is one of a series of new reports from The Business Research Company that provides manufacturing analytics market statistics, including manufacturing analytics industry global market size, regional shares, competitors with a manufacturing analytics market share, detailed manufacturing analytics market segments, market trends and opportunities, and any further data you may need to thrive in the manufacturing analytics industry. This manufacturing analytics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global manufacturing analytics market size grew from $9.92 billion in 2022 to $11.98 billion in 2023 at a compound annual growth rate (CAGR) of 20.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The manufacturing analytics market size is expected to grow to $27.27 billion in 2027 at a CAGR of 22.8%. An increase in the need for process optimization is expected to propel the growth of the manufacturing analytics market going forward. Process optimization refers to reducing or eliminating time and resource wastage, unnecessary costs, bottlenecks, and mistakes while achieving the process objective. Process optimization in manufacturing analytics adds to various benefits such as providing faster response to issues at the machine level, and improved maintenance and so leading to its growth and increasing the need for this technique. For instance, according to Camunda, a Germany-based open-source workflow, and decision automation platform, in 2020, 51% of automation initiatives are aimed at boosting efficiency and optimization. Also, according to a survey conducted by Camunda in 2020 on how process automation is a business driver for growth, half (49%) of an organization’s process automation initiatives are focused on driving business growth. The other half of the process automation initiatives highlighted ways of business optimization (27%). Therefore, an increase in the need for process optimization is driving the growth of the manufacturing analytics market. New product innovation is a key trend gaining popularity in the manufacturing analytics market. Major companies operating in the manufacturing analytics market are focused on developing technologically advanced software to strengthen their market position. For instance, in May 2022, Google Cloud Platform, offered by Google, a US-based technology company launched Manufacturing Data Engine and Manufacturing Connect that enable manufacturers to connect previously segregated assets, process and standardize data, and improve visibility from the factory floor to the cloud. The solutions enable three essential AI and analytics-based use cases–manufacturing analytics and insights, predictive maintenance, and machine-level anomaly detection–once data has been harmonized. Manufacturing Data Engine and Manufacturing Connect, both of which are now accessible, assist manufacturers in unifying their data and empowering their employees through simple analytics and AI solutions built on cloud infrastructure. In October 2020, TIBCO Software Inc., a US-based business intelligence software company, acquired Information Builders Inc for an undisclosed amount. Through this acquisition, TIBCO gained the access to a broader range of analytics and technologies, considerably boosting its capacity to assist the world's most prestigious enterprises in solving the most difficult data challenges and further unlock the potential of real-time data for making faster, better decisions. Information Builders Inc is a US-based privately held software company that offers business analytics services. Major players in the manufacturing analytics market are SAP SE, Oracle Corporation, SAS Institute Inc., Tableau Software Inc., TIBCO Software Inc., International Business Machines Corporation, Alteryx Inc., Sisense Inc., Wipro Limited, Bridgei2i Analytics Solutions, Cisco Systems Inc., FICO (Fair, Isaac and Company), Domo Inc., Neubrain, Aegis Software, MachineMetrics, and Lantek. North America was the largest region in the manufacturing analytics market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the manufacturing analytics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the manufacturing analytics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The manufacturing analytics market includes revenues earned by entities by tools and services transform real-time data into just-in-time insights and enable improved customer service. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global manufacturing analytics market is segmented - 1) By Component: Software, Services 2) By Deployment: Cloud, On Premise 3) By Application: Predictive Maintenance, Inventory Management, Supply Chain Optimization, Other Applications 4) By Industry Vertical: Semiconductor and Electronics, Energy and Power, Pharmaceutical, Automobile, Heavy Metal and Machine Manufacturing, Other Industry Verticals

Pharmaceutical drug refers to a substance created to treat, prevent, or cure an illness or other condition, or to lessen its symptoms. To list the most popular methods, drugs can be consumed orally, through a skin patch, by injection, or through an inhaler. Other vital medications made from natural materials include vaccinations, steroid hormones, human blood-plasma fractions, and antibiotics. The main types of pharmaceutical drugs are cardiovascular drugs, dermatology drugs, gastrointestinal drugs, genito-urinary drugs, hematology drugs, anti-infective drugs, metabolic disorders drugs, musculoskeletal disorders drugs, central nervous system drugs, oncology drugs, ophthalmology drugs, and respiratory diseases drugs. Cardiovascular drugs are used to treat medical conditions associated with the heart or the circulatory system (blood vessels), such as arrhythmias, blood clots, coronary artery disease, high or low blood pressure, high cholesterol, heart failure, and stroke. The drugs are administered through oral, parenteral, and others that are classified into branded and generic drugs. The various mode of purchase includes prescription-based drugs and over-the-counter drugs which are distributed by hospital pharmacies, retail pharmacies/ drug stores, and others. The pharmaceutical drug market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical drug market statistics, including pharmaceutical drug industry global market size, regional shares, competitors with a pharmaceutical drug market share, detailed pharmaceutical drug market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical drug industry. This pharmaceutical drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical drugs market is expected to grow from $ 1,136.23 billion in 2022 to $1,199.86 billion in 2023 at a compound annual growth rate (CAGR) of 5.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The pharmaceutical drugs market is expected to reach $1,848.49 billion in 2027 at a CAGR of 11.4%. The rise in sedentary jobs, busy lifestyles, and changing consumer preferences are affecting the disease profile of the world population, especially non-communicable diseases such as cancer, diabetes, and cardiovascular diseases. Long working hours, less physical activity, and unhealthy eating and drinking habits are major causes of chronic diseases such as diabetes. According to the World Health Organization, chronic disease prevalence rose by 57% globally, in the year 2020. China and India together had about 193.4 million diabetic patients in 2019 and India is expected to have about 101 million diabetic patients by 2030, thereby increasing the need for biologics drugs for diabetic patients. These factors are expected to increase the patient pool globally, thereby driving the pharmaceutical drug market during the forecast period. Interest rates globally are forecasted to rise in most of the developing and developed economies, during the forecast period, this is expected to limit new investments in the market. Most countries across the world are raising interest rates to control inflation and also to limit the flow of capital out of the country. This is likely to affect new investments in terms of expansion, research, and development of new products. For instance, the US interest rates rose to 3.5% by 2021. These factors are expected to hurt the market as borrowing money becomes expensive, thereby affecting the pharmaceuticals market growth. Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company. For example, in 2020, FDA has switched three prescription drugs to OTC including Voltaren for arthritis pain, olopatadine hydrochloride 0.1% and 0.2% (Pataday Twice Daily Relief and Pataday Once Daily Relief) for temporary relief of itchy and red eyes due to pollen, ragweed, and grass. Major companies in the pharmaceutical drugs market include Bristol-Myers Squibb, Sanofi S.A, Johnson & Johnson, Novartis AG, Bayer AG, Abbott Laboratories, GlaxosmithKline, AstraZenec, Merck & Co and CJ Corp. North America was the largest region in the pharmaceutical drugs market in 2022. Middle East is expected to be the fargest growing region in the forecast period. The regions covered in the pharmaceutical drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical drugs market report are Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Egypt, Finland, France, Germany, Hong Kong, India, Indonesia, Ireland, Israel, Italy, Japan, Malaysia, Mexico, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, UK, USA, Venezuela and Vietnam. The pharmaceutical drug market consists of sales of generic drugs, over-the-counter medications, bulk drugs, vaccines, biosimilars, and biologics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmaceutical drugs market is segmented - 1) By Type: Cardiovascular Drugs, Dermatology Drugs, Gastrointestinal Drugs, Genito-Urinary Drugs, Hematology Drugs, Anti-Infective Drugs, Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs, Central Nervous System Drugs, Oncology Drugs, Ophthalmology Drugs, Respiratory Diseases Drugs 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies/ Drug Stores, Other Distribution Channels 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Drug Classification: Branded Drugs, Generic Drugs 5) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs Subsegments Covered: Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Drugs), Acne Drugs, Dermatitis, Psoriasis, Other Drugs for Dermatology Diseases, Antacids, Antiulcerants, Vitamin And Minerals, Antiobesity, Antiemetics And Antinauseants, Antidiarrhoeals, Hormonal Contraceptives, Drugs For Benign Prostatic hypertrophy, Drugs For Infertility, Drugs For Erectile Dysfunction, Drugs For Urinary Incontinence And Overactive Bladder, Drugs For Infections And Others, Drugs For Hormonal Replacement Therapy, Diuretics, Blood Products, Anemia And Other Blood Disorder Drugs, Antibiotics, Antivirals, Antifungals, Others (Anthelminthic, Antiprotozoal), Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism), Drugs For Rheumatoid Arthritis, Muscle Relaxants, Other Musculoskeletal Disorders Drugs, Analgesics, Anti-Parkinson drugs, Anesthetics, Anti-Epileptics, Other CNS drugs, Lung Cancer Drugs, Pancreatic Cancer Drugs, Breast Cancer Drugs, Prostate Cancer Drugs, Ovarian Cancer Drugs, Colorectal Cancer Drugs, Gastric Cancer Drugs, Kidney Cancer Drugs, Brain Tumor Drugs, Thyroid Cancer Drugs, Skin Cancer Drugs, Bladder Cancer Drugs, Cervical Cancer Drugs, Blood Cancer Drugs, Others (Kaposi Sarcoma, AIDS-Related Lymphoma, Anal Cancer, Bone Cancer, Retinoblastoma, Testicular Cancer, Hepatocellular (Liver) Cancer, Mouth Cancer, Neuroblastoma), Antiglaucoma Drugs, Dry Eye Medication, Other Ophthalmological Drugs (Retinal Disorders, Anti-Infectives/Allergy), Anti-Asthmatics And COPD Drugs, Cough And Cold Preparations

Manufacturing execution system refers to comprehensive dynamic software designed to monitor, track, and document and control the process of manufacturing from raw material to end product. It acts as a functional layer between ERP (enterprise resource planning) and process control systems, by offering data to decision-makers to establish efficient and optimized production activities. The main offering of manufacturing execution systems includes software and services. The manufacturing execution system software refers to a specialist class of production-oriented software, which is designed to manage, monitor and synchronize the execution of real-time physical processes involved in converting raw materials into finished products. They are deployed through on-premise, on-demand and hybrid delivery models. These systems are used in small and medium-sized enterprises and large enterprises in industries ranging from food & beverages, oil & gas, chemicals, pulp & paper, pharmaceutical & life sciences, energy & power, water & wastewater treatment, and other industries. The manufacturing execution systems market research report is one of a series of new reports from The Business Research Company that provides manufacturing execution systems market statistics, including manufacturing execution systems industry global market size, regional shares, competitors with a manufacturing execution systems market share, detailed manufacturing execution systems market segments, market trends and opportunities, and any further data you may need to thrive in the manufacturing execution systems industry. This manufacturing execution systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global manufacturing execution system market size grew from $13.21 billion in 2022 to $14.73 billion in 2023 at a compound annual growth rate (CAGR) of 11.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The manufacturing execution system market size is expected to grow to $22.89 billion in 2027 at a CAGR of 11.7%. The increase in demand for mass production and a connected supply chain to cater to the growing population is expected to drive the manufacturing execution system market. The companies are increasingly investing in advanced software and AI-based systems to meet the fast-growing demand for mass production activities and connected supply chains. For instance, according the study published in the United Nations Industrial Development Organization, in the Q4 of 2021, global manufacturing production observed a year-on-year growth of 3.3%, following an increase of 5.8% and 17.8% in Q3 and Q2 respectively. Additionally, according to the study conducted by PwC, a Global Industry 4.0 Survey, it was reported that implementation of manufacturing execution systems in production lines contributed to a 30% increase in productivity and increased ROI from cost savings of 3% and additional revenue of 3%. Therefore, mass production and a connected supply chain are expected to boost the manufacturing execution system market. Technological innovations are a key trend gaining popularity in the manufacturing execution systems market. The companies operating in the manufacturing execution systems market are developing innovative products with advanced technologies to meet the fast-growing demand from end customers and strengthen their market position. For instance, in November 2020, Critical Manufacturing, a Portugal-based software company, launched the Industry 4.0 Manufacturing Execution System (MES). It is designed to solve the manufacturing data challenge with a unique approach that combines IIOT, MES, equipment integration and data platform elements for processing, and analytics that promises to accelerate the future of true manufacturing insights and intelligence to drive better business outcomes. In September 2021, Honeywell, a US-based company that provides modular solutions for life science operations efficiency, compliance, and digital transformations, acquired Performix Inc. for an undisclosed amount. With this acquisition, Honeywell's strategy is to construct the world's top integrated software platform for customers in the life sciences industry with the inherent potential to achieve faster compliance, enhanced dependability, and higher production throughput while maintaining the highest levels of quality. Performix Inc., is a Huston-based company involved in offering manufacturing execution system (MES) software for the pharmaceutical and biotech industries. Major players in the manufacturing execution system market are ABB Ltd., AVEVA plc, Dassault Systèmes, Honeywell International, Inc., Rockwell Automation, Inc., Siemens AG, SAP SE, General Electric Company, Oracle Corporation, Emerson Electric Co., Werum IT Solutions GmbH, Accenture, Andea Solutions, Schneider Electric SE, HCL Technologies, and SAP AG. Asia-Pacific was the largest region in the manufacturing execution system market in 2022. The regions covered in the manufacturing execution system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the manufacturing execution system market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The manufacturing execution system market includes revenues earned by entities by providing services such as business planning and logistics, manufacturing operations management, process control systems, batch control, continuous control, discrete control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global manufacturing execution system market is segmented - 1) By Offering: Software, Services 2) By Deployment: On-premise, On-demand, Hybrid 3) By Organization Size: Small and Medium Size Enterprise, Large Enterprise 4) By Process Industry: Food & Beverages, Oil & Gas, Chemicals, Pulp & Paper, Pharmaceutical & Life Sciences, Energy & Power, Water & Wastewater Management, Other Process Industries

Contract textile refers to fabrics which are designed, produced, sold, and used for commercial interiors. It is a business-to-business (B2B) arrangement in which textile manufacturers agree with companies involved in producing final products for commercial end customers. The main types of contract textiles are type A, type B, and type C. The type A segment consists of sales of type A refer to a fabric where the first marker is not served by the flame and the flame does not burn through the edges of the metal frame while it is tested before and after cleaning. The different end-users include office spaces, public buildings, healthcare, hotels, restaurants, and cafes (HORECA). The contract textile market research report is one of a series of new reports from The Business Research Company that provides contract textile market statistics, including contract textile industry global market size, regional shares, competitors with a contract textile market share, detailed contract textile market segments, market trends and opportunities, and any further data you may need to thrive in the contract textile industry. This contract textile market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global contract textile market size grew from $4.81 billion in 2022 to $5.12 billion in 2023 at a compound annual growth rate (CAGR) of 6.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The contract textile market size is expected to grow to $6.1 billion in 2027 at a CAGR of 4.5%. The rise in online shopping is driving the contract textiles market. Online shopping is a type of electronic commerce that enables buyers to transact with sellers directly over the Internet using a web browser or a mobile app. Online shopping has seen a significant surge due to the COVID-19 pandemic. People shifted from offline shopping to online shopping because of restrictions on movement. This shift has caused an increase in awareness about different types of textiles, including contract textiles. For instance, in 2020, according to the survey conducted on online consumers in 9 countries by the United Nations Conference and Trade Development, there was an increase in the percentage of online shoppers making at least one online purchase every two months during the COVID-19 outbreak. The online shoppers in pharmaceuticals increased by 9%, the cosmetics and personal care segment increased by 6%, the fashion and accessories segment increased by 2%, and such an increase was evident in other sectors as well. Therefore, the rise in online shopping is expected to propel the growth of the contract textile market. The rise in product innovations is growing in popularity and has become a key trend in the contract textile market. Innovations such as Celliant fiber are gaining popularity in the contract textile market. Celliant fiber features patented infrared fiber technology, which enhances cellular oxygenation and local circulation for improved performance, recovery, and sleep. For instance, in October 2021, The Crypton Companies, a US-based textile company, in partnership with Hologenix LLC, a producer of Celliant Infrared Technology, developed Crypton CELLIANT, the first woven upholstery fabric containing Celliant fiber. When a person sits on a chair covered with Celliant, the minerals in the fabric absorb the heat generated by the body. Thus, by temporarily increasing local blood flow in the cell tissue, performance and recovery are improved. In August 2022, Archroma, a Switzerland-based global specialty chemicals company, acquired Textile Effects business from Huntsman Corporation. With this acquisition, Huntsman Textile Effects would be well-positioned to spur growth and provide considerable value for our stakeholders, workers, and clients. This agreement would give the best-in-class cost performance for fashion companies, automotive, technical, and home textiles while protecting the environment and leading the textile industry in sustainability, innovation, and performance. Huntsman Textile Effects is a Germany-based provider of high quality dyes, chemicals and digital inks to the textile and related industries. Major players in the contract textile market are Agua Fabrics, Beaulieu International Group, Camira Fabrics Ltd., DELIUS GmbH & Co. KG., Panaz, Sunbury Design, MAHARAM, Paramount Textile Mills (P) Ltd., CTL LEATHER, C.F. STINSON, LLC, ARC-COM, and ARCHITEX. Asia-Pacific was the largest region in the contract textile market in 2022. The regions covered in the contract textile market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the contract textile market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The contract textile market includes revenues earned by entities by creating a contract with parties engaged in the production of finished goods for commercial end consumers. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global contract textile market is segmented - 1) By Product: Type A, Type B, Type C 2) By End User: Office Spaces, Public Buildings, Healthcare, Hotels, Restaurants, and Cafes (HORECA)

A pharmacy is where one can get prescription medications. It may be located inside a grocery shop, drugstore, chemist, or other establishment. Drug store refers to a location whose major activity is the selling of pharmaceuticals, medicines, and pharmaceutical preparations. Drug stores have a regular prescription department and hire a registered pharmacist on-site at all times. The main drug types of pharmacies and drug stores are prescription drugs and over-the-counter drugs. Prescription drugs refer to a drug that can be obtained only with a physician's prescription. The various types involved are community pharmacy, hospital pharmacy, clinical pharmacy, industrial pharmacy, compounding pharmacy, consulting pharmacy, ambulatory care pharmacy, regulatory pharmacy, and homecare pharmacy. The different product types included are skincare, cold and flu, dental, weight loss, vitamins, and other product types. The pharmacies and drug stores market research report is one of a series of new reports from The Business Research Company that provides pharmacies and drug stores market statistics, including pharmacies and drug stores industry global market size, regional shares, competitors with a pharmacies and drug stores market share, detailed pharmacies and drug stores market segments, market trends and opportunities, and any further data you may need to thrive in the pharmacies and drug stores industry. This pharmacies and drug stores market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global pharmacies and drug stores market size will grow from $1,126.63 billion in 2022 to $1,205.81 billion in 2023 at a compound annual growth rate (CAGR) of 7.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global pharmacies and drug stores market size is expected to grow to $1,513.65 billion in 2027 at a CAGR of 5.8%. The growing ageing population and increasing health consciousness among the global populace are likely to drive the pharmacy and drug store market. The geriatric population is more vulnerable to acquiring several diseases that increase their dependence on pharmacies and drug stores, thus indirectly affecting the market. According to the Global Health and Aging report, the number of people aged 65 or older is projected to grow to nearly 1.5 billion in 2050, with most of the increase in developing countries. Certain health conditions are expected to be a challenge to our health care system with the increasing ageing population. These conditions include cancer, dementia, an increase in the number of falls, obesity, and diabetes. Due to the increasing aging population, the number of cases is expected to increase, thus providing a growing customer base for pharmacies and drug stores. Rapidly increasing cost pressures from regulatory agencies and payers will restrain the pharmacies and drug stores market. Government budgetary pressures are leading to lower pharmacy compensation for most countries with public health care. The consolidation of pharmacy benefit management firms in the U.S. has worked similarly, driving lower costs and margins, and shifting prescription volumes to the delivery of direct or mail orders. Governments would be the largest healthcare payers in virtually every country. This, in turn, creates increased pressure on taxpayers and government spending, with consequent pharmaceutical effects. These factors are expected to have a negative impact on the pharmacies and drug stores market as they increase cost pressures from regulatory agencies and affect the market’s growth. Working long hours and drive-through locations are the major factors contributing to increasing the pharmacy and drugstore market growth. As competition has increased from mass merchandisers and supermarkets, as well as from direct mail prescription services, drug stores have been adding value in the form of 24-hour operations and drive-through pharmacies. The US Pharmacy Study measures customer satisfaction with their pharmacy experience across major chain drug stores, mass merchandisers, supermarkets, and mail-order pharmacies. The study shows that retail pharmacy businesses continue to shine when it comes to engaging patient-centric services that drive satisfaction. These convenience factors anticipate the growth of pharmacies and the drugstore market. In January 2021, AmerisourceBergen Corporation, a US-based drug wholesale company, acquired Walgreens Boots Alliance, Inc. for the amount of $6.275 billion in cash and 2 million shares of AmerisourceBergen common stock. Acquiring Alliance Healthcare will provide even stronger support for pharmacies and pharmacists across the world and integrate solutions for pharmaceutical manufacturers. Walgreens Boots Alliance, Inc. is a US-based holding company that owns the retail pharmacy chains and manufactures pharmaceuticals and distribution companies. Major players in the pharmacies and drug stores market are Walgreens Boots (WBA), CVS Health (CVS), Rite Aid (RAD), MedPlus, Rexall, Shoppers Drug Mart, Grupo Casa Saba, China Nepstar, AS Watson, and Matsumoto Kiyoshi. Asia-Pacific was the largest region in the pharmacies and drug stores market in 2022. North America was the second-largest region in the global pharmacies and drug stores market. The regions covered in the global pharmacies and drug stores market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the pharmacies and drug stores market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmacies and drug stores market include revenues earned by entities by branded prescription drugs, generic drugs, non-prescription medicines, personal health supplies, and dietary supplements, cosmetics. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global pharmacies and drug stores market is segmented - 1) By Drug Type: Prescription Drugs, OTC drugs 2) By Type: Community Pharmacy, Hospital Pharmacy, Clinical Pharmacy, Industrial Pharmacy, Compounding Pharmacy, Consulting Pharmacy, Ambulatory Care Pharmacy, Regulatory Pharmacy, Home Care Pharmacy 3) By Product Type: Skin Care, Cold and Flu, Dental, Weight Loss, Vitamins, Other Product Types

Pharmaceutical sterility testing refers to a test that is intended to show if biological parenterals made for human use contain extraneous, viable contaminating microorganisms or not. All pharmaceutical items used on patients by medical professionals must be of the highest quality and extremely safe.Otherwise, it could harm the patients. Testing for sterility assures that the offered product is suitably sterile. The main types of pharmaceutical sterility testing are in-house and outsourced. The various types of tests include sterility testing, bioburden testing, and bacterial endotoxin testing, which are used to test sterile drugs, medical devices, biologics, and therapeutics. An in vitro assay for detecting bacterial endotoxins is known as a bacterial endotoxin test. The bacterial endotoxin test detects bacterial endotoxins by lysing blood cells from horseshoe crabs. The different products used are instruments, kits and reagents, and services. The pharmaceutical sterility testing market research report is one of a series of new reports from The Business Research Company that provides pharmaceutical sterility testing market statistics, including pharmaceutical sterility testing industry global market size, regional shares, competitors with a pharmaceutical sterility testing market share, detailed pharmaceutical sterility testing market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical sterility testing industry. This pharmaceutical sterility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global pharmaceutical sterility testing market grew from $1.19 billion in 2022 to $1.29 billion in 2023 at a compound annual growth rate (CAGR) of 8.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The pharmaceutical sterility testing market is expected to grow from $2.07 billion in 2027 at a CAGR of 12.5%. An increase in the number of drug launches and rising investment in research and development (R&D) contributed to the growth of the market. Sterility is an important step in the manufacture of drugs to avoid product contamination and make the drugs free from any viable microorganisms. For instance, in March 2022, according to an article shared by Pharmaceutical Technology, a US-based independent source for information, insight, and analysis on bio/pharmaceutical formulation, the UK government has announced a $347 million (£260 million) commitment to advance research and development (R&D) and the creation of innovative treatments, tools, and diagnostics. Additionally, in December 2021, according to a report shared by IQVIA, a US-based provider of advanced analytics, technology solutions, and clinical research services, Over the next five years, until 2026, a total of 300 new medications are anticipated to be introduced; this is a large increase over the level observed on average over the previous ten years, and the drugs are anticipated to tilt toward specialty, niche, and orphan drugs. In the next five years, there will be a $196 billion increase in spending on new products, which will be roughly offset by a $188 billion decrease in brand spending owing to loss of exclusivity. Companies in the pharmaceutical testing market are introducing new pharmaceutical sterility testing products and services to enhance their product portfolio and increase their presence in the market. The companies are launching technologically superior outcomes and well-equipped services to utilize the growth potential of the rising pharmaceutical sterility market. For instance, in June 2022, STEMart, a US-based provider of integrated medical device CRO services, launched comprehensive microbiology and sterility testing for sterile, non-pyrogenic products. A variety of services are included in comprehensive microbiology and sterility testing, such as the Antibiotic Potency Test to evaluate the bioactivity or potency of specific antibiotics for medical devices. Major players in the pharmaceutical sterility testing market are Pacific Biolabs, STRERIS Corporation, Boston Analytical, Gibraltar Laboratories, Sartorius AG, Solvias AG, SGS AG, Toxikon Inc., Pace Analytical Services LLC., Charles River Laboratories International Inc., Nelson Laboratories Inc., Rapid Micro Biosystems Inc., BioMerieux, Merck KGaA, Wuxi AppTec, Sotera Health LLC., Dynalabs, and Infinity. North America was the largest region in the pharmaceutical sterility testing market in 2022. The Middle East is expected to be the fastest growing region in the global pharmaceutical sterility testing market during the forecast period. The regions covered in the global pharmaceutical sterility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the pharmaceutical sterility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The pharmaceutical sterility testing market includes revenues earned by entities by membrane filtration, direct transfer (product immersion), and product flush. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain or as part of other products. The global pharmaceutical sterility testing market is segmented - 1) By Sample: Sterile Drugs, Medical Devices, Biologics, and Therapeutics 2) By Product Type: Instruments, Kits and Reagents, Services 3) By Type: In-House, Outsourcing 4) By Test Type: Sterility Testing, Bioburden Testing, and Bacterial Endotoxin Testing 5) By End- User: Compounding Pharmacies, Medical Devices Companies, Pharmaceutical Companies